- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Expert Perspectives on BOLT clinical trial data
John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.
EP: 1.Data Review of the Efficacy and Safety of Vismodegib in Advanced Basal Cell Carcinoma (EVRIANCE Trial)
EP: 2.Expert Perspectives on EVRIANCE clinical trial data
EP: 3.Data Review of 2 doses of Sonidegib in Advanced Basal Cell Carcinoma (BOLT Trial)
EP: 4.Expert Perspectives on BOLT clinical trial data
Jonathan S Zager, MD, FACS, FSSO
Moffitt Cancer Center
Tampa, Florida
Lilia Correa-Selm, MD, FAAD, FACMS
Moffitt Cancer Center
Tampa, Florida
Aaron Farberg, MD
Bare Dermatology
Dallas, Texas
John Strasswimmer, MD, PhD
Florida Atlantic University
Delray Beach, Florida
Andrew Weinstein, MD, MPH, FAAD
Boynton Beach Skin, University of Miami
Boynton Beach and Coral Gables, Florida
Series Description: Experts in dermatology discuss the clinical trial data from the BOLT and EVRIANCE clinical trials and review patient cases related to the management of patients with locally advanced basal cell carcinoma treated with sonidegib and vismodegib.
Segment Description: John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.
